DTZ Berlin selects C-RAD’s cutting-edge SIGRT solution
C-RAD announced today an order for the newly released Catalyst+ HD™ and Sentinel 4DCT™ for Diagnostic and Therapy Center (DTZ) in Berlin Germany. The order includes multiple systems for two of their treatment sites and a multiyear service agreement.
DTZ Berlin is a privately-owned health care provider with sites at two locations in Berlin, covering medical services from radiology, nuclear medicine as well as internal medicine and radiotherapy.
Dr. Matthias Lampe, Medical Director of the DTZ at the OZB Onkozentrum Berlin, comments: "From initial diagnosis right through to the end of treatment, the patient is at the heart of everything we do and receives personalized, holistic care. We are delighted that the most modern diagnostic and therapeutic devices are available at both locations, the DTZ at Frankfurter Tor and the DTZ at OZB Onkozentrum Berlin. PET/CT with contactless respiratory gating improves the diagnostic data and thus allows the exact position and extent of the tumour to be identified, meaning it can be treated with pinpoint accuracy. By combining the technology with the expertise of DTZ Berlin staff, we can ensure the best possible cancer treatment for our patients."
The systems will be delivered with the complete software suite including modules for Respiratory Gating, Patient Setup & Positioning and Motion Monitoring and a dedicated software that supports stereotactic treatments. The solution comprises C-RAD ‘s unique patient feedback solution cLight. The C-RAD SIGRT system provides the customer with a tool for accurate patient setup prior to the treatment and continuous monitoring of the patient during a treatment fraction. The technology provides accuracy and safety for the patient to support high precision treatment techniques.
Dr. Hendrik Herm, Head of Radiation Oncology stated: “Part of today’s standard treatment protocols is to mark the tumor on the skin for the patient positioning. We believe that the C-RAD technology allows us to reduce these markings significantly, which certainly increases the patient comfort.”
C-RAD Sentinel 4DCT is an easy-to-use, laser-based optical surface scanning system with functionality for 4D CT reconstruction and gated imaging in a CT room. It also provides reference images for patient positioning. The system is capturing the patient position, based on an optical 3D camera. This technology does not require any patient contact, which is especially appreciated due to hygienic advantages.
“The implementation of C-RAD’s cutting-edge technology is great news for the cancer patients in Berlin. C-RAD is excited to commence the cooperation with the team at DTZ Berlin.” says Tim Thurn, CEO and President of C-RAD AB, “Surface tracking is on its way to become standard of care within radiation therapy for multiple treatment indication. The Catalyst+ system combines C-RAD patented and proven technology with an advanced software platform designed to demonstrate a new performance-level in optical surface tracking.”
The order amounts to a total just above 11 MSEK and includes the delivery of the systems and a service contract. Delivery and installation are expected to commence in fall of this year. The last system is expected to be installed in 2021.
About DTZ Berlin
DTZ Berlin is one of Germany’s largest licensed specialist oncology facilities, founded by Prof. Wolfgang Mohnike, with an experience of 30 years in diagnostic and treatment. The facility comprises two locations in Berlin and four specialist areas, which are closely integrated and can draw on state-of-the art equipment. These include two diagnostic centers for nuclear medicine and radiology and two treatment centers, one for interventional oncology and radionuclide therapy, the other for radiotherapy.
These four specialist departments are supported by their own in-house radiochemistry facilities and Germany’s only outpatient cyclotron. Along with medical expertise, DTZ Berlin is also equipped with state-of-the-art, high-performance diagnostic and therapeutic equipment – from innovative hybrid imagery to high-precision radiotherapy machinery – all connected using specialist medical software.
About C-RAD
C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit http://www.c-rad.com
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com
This information is information that C-RAD AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11:15 CET on June 30, 2020.